CardieX is a digital healthcare company redefining the way hypertension, cardiovascular disease (CVD), and other major vascular diseases are clinically diagnosed and managed. Our vision is to be the leading provider of home, wearable, healthcare, clinical trial, and remote patient monitoring solutions for the world’s most common health disorders including hypertension, CVD, Alzheimer’s disease, chronic kidney disease (CKD), and other major vascular health conditions.

Our SphygmoCor vascular biometric technology measures arterial health by collecting clinically meaningful digital vascular biomarkers using novel sensors. These biomarkers represent key indicators of vascular health including, but not limited to, central blood pressures (cBP), vascular stiffness, vascular age, and heart stress. SphygmoCor is trusted by certain of the world’s largest pharmaceutical companies and healthcare systems to measure arterial health.

Our ATCOR division pioneered the SphygmoCor technology and focuses on servicing specialist health care providers, on-site clinical trials, research programs, and hospital networks with a variety of proprietary vascular biomarker solutions. ATCOR’s solutions have been used in 46 pharmaceutical clinical trials to-date, spanning over 1,700 global study sites, and been featured in over 2,000 peer-reviewed studies published in leading medical journals.

Our CONNEQT subsidiary develops new devices and digital solutions strategically targeted to consumer health, general health care providers, remote patient monitoring, decentralized clinical trials, and home health.

The group manufacturing and R&D operations are located in Sydney, Australia. The American subsidiary, ATCOR, is headquartered in Naperville, Illinois. Group executive offices are located in Newport Beach, California, and business development for Asian markets is located in Shanghai.